BMRN BioMarin Pharmaceutical, Inc.

NASDAQ
$56.12

BioMarin Pharmaceutical, Inc. (BMRN) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.8% since its last earnings release on November 2, 2026.

BioMarin Pharmaceutical Beat Expectations, Lowers Guidance
Monday, November 2, 2026 · 4:03 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:05 PM ET
Earnings Whisper
-
vs $0.80 (GAAP)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $56.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioMarin Pharmaceutical, Inc.

Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.